<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04553419</url>
  </required_header>
  <id_info>
    <org_study_id>ASAP-CF</org_study_id>
    <nct_id>NCT04553419</nct_id>
  </id_info>
  <brief_title>Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF</brief_title>
  <acronym>ASAP-CF</acronym>
  <official_title>Antibiotic Treatment Of Staphylococcus Aureus In Stable People With CF (ASAP-CF) Clinical Research Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of British Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital for Sick Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of British Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded study that aims to assess the effect of an oral&#xD;
      antibiotic called Cephalexin (150 mg/kg/day) compared to placebo in clinically stable&#xD;
      children with cystic fibrosis who have grown a bacteria called MSSA (methicillin-susceptible&#xD;
      Staphylococcus aureus) over the course of 2 weeks.&#xD;
&#xD;
      A sensitive technique called MBW (multiple breath washout) will be used to look at how well&#xD;
      the participants lungs are functioning during the study and to see if the antibiotic improves&#xD;
      function. The primary outcome of the study will be the relative change in the MBW measurement&#xD;
      (LCI2.5) between day 0 and day 14 of study treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 27, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The relative change in LCI2.5 between day 0 and day 14 (relative change = [LCI2.5 at day 14-LCI2.5 at day 0]/LCI2.5 at day 0).</measure>
    <time_frame>14 days from randomization</time_frame>
    <description>Lung clearance index (LCI) as measured using the multiple breath nitrogen washout (MBW) technique with the Exhlayzer D (Eco Medics, Durnten SUI) device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next pulmonary exacerbation</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in percent predicted FEV1 between day 0 and day 14</measure>
    <time_frame>14 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in FEV1 (mL) between day 0 and day 14</measure>
    <time_frame>14 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change in LCI5 between day 0 and day 14.</measure>
    <time_frame>14 days from randomization</time_frame>
    <description>Lung clearance index (LCI) as measured using the multiple breath nitrogen washout (MBW) technique with the Exhlayzer D (Eco Medics, Durnten SUI) device.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change in the CFQ-R(R) between day 0 and day 14.</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Cystic fibrosis questionnaire - revised (respiratory domain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MSSA airway culture positivity at day 14</measure>
    <time_frame>14 days from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time until next growth of MSSA on clinical microbiology samples</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new CF respiratory pathogens (P. aeruginosa etc) from clinical respiratory samples</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cephalexin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral cephalexin (available in capsule or suspension format) dosed at 150 mg/kg/day. Doses will be administered 3 times a day for 2 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be available in both capsule and suspension format. Doses will be administered 3 times a day for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cephalexin</intervention_name>
    <description>Cephalexin capsule: TEVA Cephalexin Cephalexin suspension: LUPIN Cephalexin</description>
    <arm_group_label>Cephalexin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Cellulose capsules or suspension</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of CF as evidenced by one or more clinical feature consistent with the CF&#xD;
             phenotype or positive CF newborn screen AND one or more of the following criteria:&#xD;
&#xD;
               1. A documented sweat chloride ≥ 60 mEq/L by quantitative pilocarpine iontophoresis&#xD;
                  (QPIT)&#xD;
&#xD;
               2. A documented genotype with two disease-causing mutations in the CFTR gene&#xD;
&#xD;
          2. Age 3 years and over, up to 16th birthday.&#xD;
&#xD;
          3. Weight ≥ 10.0kg&#xD;
&#xD;
          4. No increase in lower respiratory tract symptoms from baseline for 28 days.&#xD;
&#xD;
          5. At least one episode of MSSA growth on airway culture in the past 24 months.&#xD;
&#xD;
          6. Successful MBW test occasion at the Screening Visit, per the assessment of the Site&#xD;
             MBW Operator.&#xD;
&#xD;
          7. Informed consent by participant or parent/legal guardian with written assent where&#xD;
             age-appropriate.&#xD;
&#xD;
        Randomization inclusion at each visit(applied after every Study Visit in the Phase 1)&#xD;
&#xD;
          1. Growth of isolated MSSA on bacterial airway culture from this Study Visit.&#xD;
&#xD;
          2. Acceptable MBW test at this Study Visit, per the assessment of the Site MBW Operator.&#xD;
&#xD;
          3. Participant willing to be randomised.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Change of any respiratory medications within 28 days of enrollment (i.e. recent&#xD;
             increase in pancreatic enzyme dosing, or similar, is not an exclusion).&#xD;
&#xD;
          2. Chronic infection (&gt;=50% positive airway cultures over the previous 12 months) with&#xD;
             any of the following: Pseudomonas aeruginosa, Burkholderia cepacia complex,&#xD;
             Stenotrophomonas maltophilia or Achromobacter spp, MRSA or any non-tuberculous&#xD;
             mycobacteria.&#xD;
&#xD;
          3. Chronic daily antibiotic use (oral, inhaled or intravenous; including azithromycin or&#xD;
             cycling month inhaled antibiotics).&#xD;
&#xD;
          4. Systemic corticosteroid use for any indication within 28 days.&#xD;
&#xD;
          5. Allergic bronchopulmonary aspergillosis (ABPA) requiring corticosteroid therapy within&#xD;
             12 months.&#xD;
&#xD;
          6. Known allergy to cephalexin or other cephalosporins.&#xD;
&#xD;
          7. Previous organ transplantation.&#xD;
&#xD;
          8. Clinical findings that, in the opinion of the Site Investigator, would compromise the&#xD;
             safety of the participant or the quality of the study data.&#xD;
&#xD;
        Randomisation exclusion(applied after every Study Visit in the Phase 1)&#xD;
&#xD;
          1. Increase in respiratory (upper or lower) symptoms from baseline in the previous 28&#xD;
             days.&#xD;
&#xD;
          2. Change of any respiratory medications within 28 days.&#xD;
&#xD;
          3. New diagnosis of allergic bronchopulmonary aspergillosis (ABPA) since previous&#xD;
             encounter.&#xD;
&#xD;
          4. New use of chronic daily antibiotics since previous encounter.&#xD;
&#xD;
          5. Clinical findings that, in the opinion of the Site Investigator, would compromise the&#xD;
             safety of the participant or the quality of the study data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Rayment, MDCM</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of British Columbia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fareeha Khan</last_name>
    <phone>604-875-2345</phone>
    <phone_ext>7606</phone_ext>
    <email>fareeha.khan@bcchr.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>BC Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fareeha Khan</last_name>
      <phone>604-875-2345</phone>
      <phone_ext>7606</phone_ext>
      <email>fareeha.khan@bcchr.ca</email>
    </contact>
    <contact_backup>
      <last_name>Alam Lakhani</last_name>
      <phone>604-875-2345</phone>
      <phone_ext>7606</phone_ext>
      <email>alam.lakhani@cw.bc.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Rayment</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Hospital For Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Felix Ratjen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of British Columbia</investigator_affiliation>
    <investigator_full_name>Jonathan Rayment</investigator_full_name>
    <investigator_title>Clinical Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cephalexin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

